Oxaliplatin with Biweekly, Low Dose Leucovorin and Bolus and Continuous Infusion 5-fluorouracil (Modified FOLFOX 4) as First-line Therapy for Patients with Metastatic Colorectal Cancer
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose: To determine the activity and toxicities of low dose leucovorin (LV) plus fluorouracil (5-FU) regimen, combined with oxaliplatin every two weeks (modified FOLFOX 4), as a first-line therapy for patients with metastatic colorectal cancer. Materials and Methods: Between March 2001 and August 2003, fifty-five patients were enrolled in this study. Patients were treated with oxaliplatin 85 mg/m2 as a 2-hour infusion at days 1 plus LV 20 mg/m2 over 10 minutes, followed by 5-FU bolusa 400 mg/m2 bolus and 22 hour continuous infusion of 600 mg/m2 5-FU at day 1~2. This treatment was repeated in 2 week intervals. Results: The objective response rate was 40% on an intent-to-treatment analysis. Three patients (6%) demonstrated a complete response and nineteen patients (38%) showeda partial response. Sixteen patients (32%) showed a stable disease and eleven patients (22%) progressed during the course of the treatment. The median time to progression and overall survival time wereas 6.6 months (95% CI: 4.98~8.02 months) and the median overall survival time was 17.0 months (95% CI: 9.15~24.85 months) from the start of the chemotherapy, respectively. A total of 275 cycles were analyzed for toxicity. Major hematologic toxicities included grade 1~2 anemia (23.5%), neutropenia (25.3%) and thrombocytopenia (10.6%). There were only 2 cycles of neutropenic fever. The most common non- hematologic toxicities were grade 1~2 nausea/vomiting (10.9%), diarrhea (9.1%) and grade 1 neuropathy (18.0%). There was no treatment related death. Conclusion: The modified folfox 4 regimen is safe and effective regimen as a first-line therapy in advanced colorectal cancer patients.(Cancer Res Treat. 2004;36:115-120)
Abstract
Purpose: To determine the activity and toxicities of low dose leucovorin (LV) plus fluorouracil (5-FU) regimen, combined with oxaliplatin every two weeks (modified FOLFOX 4), as a first-line therapy for patients with metastatic colorectal cancer. Materials and Methods: Between March 2001 and August 2003, fifty-five patients were enrolled in this study. Patients were treated with oxaliplatin 85 mg/m2 as a 2-hour infusion at days 1 plus LV 20 mg/m2 over 10 minutes, followed by 5-FU bolusa 400 mg/m2 bolus and 22 hour continuous infusion of 600 mg/m2 5-FU at day 1~2. This treatment was repeated in 2 week intervals. Results: The objective response rate was 40% on an intent-to-treatment analysis. Three patients (6%) demonstrated a complete response and nineteen patients (38%) showeda partial response. Sixteen patients (32%) showed a stable disease and eleven patients (22%) progressed during the course of the treatment. The median time to progression and overall survival time wereas 6.6 months (95% CI: 4.98~8.02 months) and the median overall survival time was 17.0 months (95% CI: 9.15~24.85 months) from the start of the chemotherapy, respectively. A total of 275 cycles were analyzed for toxicity. Major hematologic toxicities included grade 1~2 anemia (23.5%), neutropenia (25.3%) and thrombocytopenia (10.6%). There were only 2 cycles of neutropenic fever. The most common non- hematologic toxicities were grade 1~2 nausea/vomiting (10.9%), diarrhea (9.1%) and grade 1 neuropathy (18.0%). There was no treatment related death. Conclusion: The modified folfox 4 regimen is safe and effective regimen as a first-line therapy in advanced colorectal cancer patients.(Cancer Res Treat. 2004;36:115-120)
참고문헌 (25)
- "Cancer incidence in Korea", 34, pp.405~408 (2002)
- "Cancer Facts and Figures-2000" (2000), American Cancer Society
- "Survival benefit of chemotherapyin metastatic colorectal cancer:A meta-analysis of randomisedcontrolled trials", 82, pp.1789~1794 (2000)
- "The changing face of chemotherapyin colorectal cancer", 84, pp.1~7 (2000)
- "Antitumor activity ofoxaliplatin in combination with 5-fluorouracil and the thymidylatesynthase inhibitor AG337 in human colon,breast,andovarian cancers", 8, pp.876~885 (1997)
- "Two consecutive phase II studies of oxaliplatin for treatment of patients with advanced colorectalcarcinoma who were resistant to previous treatment withfluoropyrimidines", 7, pp.95~98 (1996)
- "A phaseII trial of oxaliplatin as first-line chemotherapy in metastaticcolorectal cancer patients", 8, pp.2739~2744 (1998)
- "Chronomodulatedversus fixed infusion rate delivery of ambulatorychemotherapy with oxaliplatin,5-fluorouracil and folinic acidin patients with colorectal cancer metastases:A randomizedmulti-institutional trial", 86, pp.1608~1617 (1994)
- "Oxaliplatin with high-dose leucovorin and 5-fluorouracil48-hour continuous infusion in pretreated metastatic colorectalcancer", 33, pp.214~219 (1997)
- "A phase II study of oxaliplatin combined with 5-fluorouracil and leucovorin(Mayo Clinic regimen)in 5-fluorouracil refractory colorectal cancer", 34, pp.218~222 (2002)
- "Irinotecan combined with fluorouracilcompared with fluorouracil alone as first-line treatmentfor metastatic colorectal cancer: A multicentre randomisedtrial", 355, pp.104~11047 (2000)
- "Leucovorin and fluorouracilwith or without oxaliplatin as first-line treatment inadvanced colorectal cancer", 18, pp.2938~2947 (2000)
- "Phase III multicenterrandomized trial of oxaliplatin added to chronomodulatedfluorouracil-leucovorin as first-line treatment of metastaticcolorectal cancer", 18, pp.136~147 (2000)
- "N9741: Oxaliplatin (oxal) orCPT-11+5-fluorouracil (5FU)", leucovorin (LV) or oxal+CPT-11 in advanced colorectal cancer(CRC). Updated efficacy andquality of life (QOL) data from an intergroup study, 2003, pp.22, 252~
- "Safety and ToxicityAnalysis of Oxaliplatin Combined With Fluorouracil or as aSingle Agent in Patients With Previously Treated AdvancedColorectal Cancer", 21, pp.2904~2911 (2003)
- "Phase II study of capecitabine and oxaliplatin infirst- and second-line treatment of advanced or metastaticcolorectal cancer", 20, pp.1759~1766 (2002)
- "High-dose intensity oxaliplatin added to the simplifiedbimonthly leucovorin and 5-fluorouracil regimen as secondlinetherapy for metastatic colorectal cancer(FOLFOX 7).", 37, pp.1000~1005 (2001)
- "Capecitabine-oxaliplatin combination (XELOX) an effective first-linetherapy for patietnspatients with metastatic colorectal cancer:Survival updates of an international phase II trial", pp.13~80 (2002)
- "Randomizedtrial comparing three different schedules of infusional5FU and raltitrexed alone in first line metastatic colorectalcancer Final results of the Federation Francophone de CancerologieDigestive 9601 trial", 13(71) (2002)
- "Effects of different schedules of oxaliplatin treatment on theperipheral nervous system of the rat", 37, pp.2457~2463 (2001)
- "Clinical aspectsand molecular basis of oxaliplatin neurotoxicity:Currentmanagement and development of preventive measures", 29, pp.2133~ (2002)
- "Neuroprotectiveeffect of reduced glutathione on oxaliplatin-based chemotherapyin advanced colorectal cancer:A randomized,double-blind,placebo-controlled trial", 20, pp.3478~3483 (2002)
- "Biweekly ChemotherapyWith Oxaliplatin, Irinotecan, Infusional Fluorouracil,and Leucovorin: A Pilot Study in Patients With MetastaticColorectal Cancer", 20, pp.4006~4014 (2002)
- "Results of a phase III trial of bevacizumab in combinationwith bolus irinotecan leucovorin as first-linetherapy in subjects with metastatic CRC", 22 (2003)
- "Cetuximab(C225) alone or in combination with irinotecan in patients withepidermal growth factor receptor-positive, irinotecan-refractorymetastatic colorectal cancer", 22(252) (2003)